Advertisement
Table 1 Patients’ characteristics
| Variable | All (n = 104) | Homogeneous perfusion (n = 79) | Inhomogeneous perfusion (n = 25) | p value |
|---|---|---|---|---|
| Age at date of HTx (years) | 49.4 ± 12.6 | 49.4 ± 12.6 | 49.4 ± 13.3 | 0.98 |
| Gender (men/women) | 86 (83 %)/18 (17 %) | 65 (82 %)/14 (18 %) | 21 (84 %)/4 (16 %) | 0.46 |
| BMI | 25.8 ± 3.3 | 25.9 ± 3.5 | 25.3 ± 2.8 | 0.51 |
| Reason for HTx | ||||
| CAD | 50 (48 %) | 37 (47 %) | 13 (52 %) | 0.68 |
| Dilated cardiomyopathy | 44 (42 %) | 35 (44 %) | 9 (36 %) | 0.07 |
| Others | 10 (10 %) | 7 (9 %) | 3 (12 %) | 0.14 |
| Systemic hypertension | 88 (85 %) | 65 (82 %) | 23 (92 %) | 0.78 |
| Diabetes mellitus | 18 (17 %) | 14 (18 %) | 4 (16 %) | 0.68 |
| Hypercholesterolemia | 76 (73 %) | 58 (73 %) | 18 (72 %) | 0.25 |
| Renal failure | 71 (68 %) | 51 (65 %) | 20 (80 %) | 0.22 |
| Malignancy | 14 (13 %) | 13 (16 %) | 1 (4 %) | 0.12 |
| Peripheral artery disease | 12 (12 %) | 10 (13 %) | 2 (8 %) | 0.55 |
| Beta blockers | 26 (25 %) | 19 (24 %) | 7 (28 %) | 0.55 |
| Calcium channel antagonists | 88 (85 %) | 72 (91 %) | 16 (64 %) | 0.04 |
| ACE inhibitors | 27 (26 %) | 19 (24 %) | 8 (32 %) | 0.39 |
| Statins | 94 (90 %) | 73 (92 %) | 21 (84 %) | 0.77 |
| Coronary interventions in the follow-up | 15 (15 %) | 13 (16 %) | 2 (8 %) | 0.06 |
| MACE (incl. interventions) | 20 (19 %) | 15 (19 %) | 5 (20 %) | 0.14 |
| Deaths in observation period | 11 (11 %) | 7 (9 %) | 4 (16 %) | 0.26 |
